BSH 2024 | The current treatment landscape for patients with T-cell prolymphocytic leukemia
Dima El-Sharkawi, MBBS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, briefly summarizes the current treatment landscape for patients with T-cell prolymphocytic leukemia (T-PLL). T-PLL is an extremely rare, aggressive mature T-cell leukemia and clinical outcomes remain poor for patients with the malignancy despite improvements in the understanding of the disease pathophysiology over the past two decades. While the standard treatment option continues to be alemtuzumab, Dr El-Sharkawi expresses optimism that novel drugs for T-PLL will be developed in the future. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Abbvie; AstraZeneca; Beigene; Gilead, Janssen; Lily; Roche; Takeda
Conference/ Travel support: Abbvie; Novartis; Roche
Ad boards: Abbvie; ASTEX; AstraZeneca; Beigene; Janssen; Kyowa Kiirin
